D59.32
Hereditary hemolytic-uremic syndrome
Clinical Classification Guidelines
Inclusion Terms
- Atypical hemolytic uremic syndrome with an identified genetic cause
Code Also
- , if applicable:
- defects in the complement system (D84.1)
- methylmalonic acidemia (E71.120)
Medical Intelligence & Overview
Hereditary hemolytic-uremic syndrome (HUS) is a rare, genetic disorder characterized by the destruction of red blood cells, low platelet count, and kidney failure. Known also as atypical HUS, this condition differs from typical HUS because it does not usually follow an infection and is caused by genetic factors. It falls under the ICD-10 code D59.32, indicating its hereditary and atypical nature. Understanding this condition is important for those affected, as it significantly impacts health and requires specialized management.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting the complement system, which is part of the immune system that helps fight infections. Inherited defects in genes responsible for regulating blood clotting and immune responses. Family history of similar symptoms or diagnosed with heriditary HUS. Rarely, acquired factors can trigger symptoms in genetically predisposed individuals, but the primary cause remains genetic mutations.
Key Symptoms: Itching or feeling fatigued due to anemia caused by the destruction of red blood cells. Paleness or jaundice resulting from breakdown of red blood cells. Decreased urine output or dark-colored urine indicating kidney involvement. Swelling in the legs, ankles, or face (edema), often due to kidney dysfunction. High blood pressure which may occur as a consequence of kidney problems. General weakness and potential neurological symptoms in severe cases.
Diagnostic & Treatment
Diagnosis Path: Diagnosing hereditary HUS involves a combination of clinical assessments, laboratory tests, and genetic testing. Healthcare providers may perform blood tests to measure hemoglobin levels, platelet counts, kidney function, and markers of hemolysis. Urinalysis can reveal protein or blood in the urine. Additional testing includes genetic analysis to identify mutations associated with the complement system, helping confirm the hereditary nature of the disorder.
Treatment Protocols: Management of hereditary HUS focuses on controlling symptoms, preventing complications, and addressing the underlying genetic factors. Key approaches include: - Plasma exchange or infusion to remove or replace abnormal blood components. - Medications such as complement inhibitors (e.g., eculizumab), which target part of the immune system involved in the disease process. - Supportive therapies like blood transfusions and dialysis if kidney failure occurs. - Regular monitoring to detect early signs of worsening or recurrence. - Genetic counseling for affected families to understand inheritance patterns and risks. Because of the complexity and potential severity of the condition, treatment plans are tailored to each individual, often involving a multidisciplinary team of specialists.
Clinical Advice & FAQs
Billing Guidance
Is D59.32 a billable ICD-10 code?
Yes, D59.32 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D59.32?
Clinical documentation must specify the nature of Hereditary hemolytic-uremic syndrome and any associated comorbidities for accurate reporting.
Cite this Clinical Reference